Pheon Therapeutics
Pheon Therapeutics is a leading ADC (Antibody-Drug Conjugate) specialist developing next-generation ADCs for hard-to-treat cancers. Leveraging two decades of ADC experience, Pheon aims to treat difficult solid tumors with a novel pipeline of ADCs. The company employs a methodical approach to ADC development, using monoclonal antibodies against both novel and validated targets, armed with proprietary payloads or off-the-shelf linker payloads, balancing safety and efficacy. Pheon’s mission is to transition its lead asset into clinical development and build a pipeline addressing unmet medical needs across multiple cancer types. Backed by expert healthcare investors, Pheon boasts a proven leadership team in ADC engineering, clinical strategy, and business.
Industries
Nr. of Employees
small (1-50)
Pheon Therapeutics
UK: Innovation House, Innovation Way, Discovery Park, Sandwich, Kent, CT13 9FF, United Kingdom; USA: 139 Main Street, Suite 201, Cambridge, MA 02142, USA
Patents
Anti-proliferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines
US-11912700-B2
View DetailsAnti-liferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines
US-10975074-B2
View DetailsSubstituted 6a,7,8,9,10,12-hexahydrobenzo[e]pyrido[1,2-a][1,4]diazepines as anti-proliferative agents
US-10975072-B2
View Details
Anti-proliferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines
US-11912700-B2
View DetailsAnti-liferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines
US-10975074-B2
View DetailsSubstituted 6a,7,8,9,10,12-hexahydrobenzo[e]pyrido[1,2-a][1,4]diazepines as anti-proliferative agents
US-10975072-B2
View DetailsProducts
Pipeline of first‑in‑class and differentiated ADC assets
A privately developed pipeline comprising multiple first‑in‑class ADC candidates targeting a novel antigen overexpressed in a broad range of solid tumours; constructs utilize varied linker‑payload chemistries and are advanced through preclinical development toward clinical proof of concept.
Lead first‑in‑class ADC program entering Phase 1
Lead ADC candidate selected for first‑in‑human evaluation (Phase 1), targeting a novel antigen highly expressed in multiple solid tumour types; intended to establish clinical proof of concept.
Pipeline of first‑in‑class and differentiated ADC assets
A privately developed pipeline comprising multiple first‑in‑class ADC candidates targeting a novel antigen overexpressed in a broad range of solid tumours; constructs utilize varied linker‑payload chemistries and are advanced through preclinical development toward clinical proof of concept.
Lead first‑in‑class ADC program entering Phase 1
Lead ADC candidate selected for first‑in‑human evaluation (Phase 1), targeting a novel antigen highly expressed in multiple solid tumour types; intended to establish clinical proof of concept.
Services
Exclusive licensing and co-development partnerships to obtain fully human antibody assets and advance them into ADC programs through preclinical development.
Exclusive licensing and co-development partnerships to obtain fully human antibody assets and advance them into ADC programs through preclinical development.
Expertise Areas
- Antibody-drug conjugate (ADC) development
- Early‑phase oncology clinical development
- CMC strategy and biologics manufacturing
- Antibody discovery and engineering
Key Technologies
- Antibody-drug conjugates (ADC)
- Linker-payload chemistry
- Topoisomerase‑1 inhibitor payloads
- High drug‑antibody ratio (DAR) constructs
News & Updates
A conference held in London from 13-16 March 2023.
A conference held in San Francisco from 9-13 January 2023.
A conference held in London from 15-17 November 2022.
An event held in London on 14 November 2022.
A conference held in London from 13-16 March 2023.
A conference held in San Francisco from 9-13 January 2023.
A conference held in London from 15-17 November 2022.
An event held in London on 14 November 2022.